Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications
Lund, Sweden | September 17, 2009 | Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications.
This collaboration combines the strengths of both companies’ technologies to develop a next generation immunotherapeutic treatment that could provide systemic anti-cancer effect and immunity, with minimal systemic side effects for the benefit of cancer patients.
Dr Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience, commented: “We are very pleased to work with BioInvent, a company with proven success in developing antibody-based drugs, and we believe that Alligator Biosciences technology and know-how will add a substantial value and success to this joint program. Further, it also confirms that Alligator Biosciences technology is valuable and needed for the development of next generation antibody based drugs”. According to the terms, the parties will after an initial research phase share costs and revenues equally.
Alligator Bioscience AB is a privately owned drug discovery and development company focused on optimization of biopharmaceuticals using it’s proprietary protein optimization technology FIND® (Fragment INduced Diversity). FIND® technology can redesign virtually any characteristics of a protein that can be translated into significant clinical benefits, including higher efficacy and potency, improved safety profile and decreased immunogenicity. The technology offers unique opportunities to discover novel protein drug candidates as well as creating second generation biopharmaceuticals. Founded in 2001 in Lund, Sweden, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical and biotech industry, improving customers’ proteins and helping them to build more competitive pipelines.
SOURCE:Alligator Bioscience AB
Post Views: 63
Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications
Lund, Sweden | September 17, 2009 | Alligator Bioscience AB today announced a research and option agreement with BioInvent International AB to co-develop an antibody-based drug for oncology indications.
This collaboration combines the strengths of both companies’ technologies to develop a next generation immunotherapeutic treatment that could provide systemic anti-cancer effect and immunity, with minimal systemic side effects for the benefit of cancer patients.
Dr Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience, commented: “We are very pleased to work with BioInvent, a company with proven success in developing antibody-based drugs, and we believe that Alligator Biosciences technology and know-how will add a substantial value and success to this joint program. Further, it also confirms that Alligator Biosciences technology is valuable and needed for the development of next generation antibody based drugs”. According to the terms, the parties will after an initial research phase share costs and revenues equally.
Alligator Bioscience AB is a privately owned drug discovery and development company focused on optimization of biopharmaceuticals using it’s proprietary protein optimization technology FIND® (Fragment INduced Diversity). FIND® technology can redesign virtually any characteristics of a protein that can be translated into significant clinical benefits, including higher efficacy and potency, improved safety profile and decreased immunogenicity. The technology offers unique opportunities to discover novel protein drug candidates as well as creating second generation biopharmaceuticals. Founded in 2001 in Lund, Sweden, Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical and biotech industry, improving customers’ proteins and helping them to build more competitive pipelines.
SOURCE:Alligator Bioscience AB
Post Views: 63
